Skip to main content
. Author manuscript; available in PMC: 2011 Sep 1.
Published in final edited form as: Surg Oncol Clin N Am. 2010 Jan;19(1):101–113. doi: 10.1016/j.soc.2009.09.004
# Patients
Randomized		 Study
Groups		 Stratification Significance
Demonstrated		 % Change
Identified in
Trial
147 400 mg imatinib daily n = 73

600 mg imatinib daily n = 74		 None No difference in progression-free survival p = NS